Pioneers in Molecular and
Autologous Medicine

Our vision is to create a world where aging and pain no longer have negative impact on the quality of life – by slowing down or even reversing disease progression and tissue aging. 

Who we are

Orthogen AG is a privately held research-based biotech company, founded in Düsseldorf, Germany. We have been developing patented medical platform technologies for targeted therapies engaging autologous and regenerative medicine. These proprietary applications span various research fields, including orthopedics, veterinary medicine and aesthetics.

>25

years

of research in molecular and autologoous medicine

>400.000

treatments

with the help of our platform technologies worldwide

130

scientific publications & academic theses

about our approaches in international scientific journals or universities

Our Mission

At Orthogen, our mission is to discover, develop and deliver novel therapies, based on autologous technologies. These can address major unmet needs in chronic diseases related to biomolecular changes including inflammation, oxidative stress and diminished regenerative potential. Our goal is to treat the underlying disease mechanisms together with symptoms.

For the purpose of research, we successfully worked or cooperated with the following institutions amongst others:

 

Medical Fields

With our core molecular technologies, we continue to develop new clinical indications.

Veterinary

Orthopedics
&
Pain Management

Aesthetics

Dedicated to research, we strive for new approaches with the anticipation to alter the course of medicine and deliver concrete solutions in the best interest of the patient.

Peter Wehling, MD, PhD
CEO and Founder of Orthogen AG

Ernst-Schneider-Platz 1
40212 Düsseldorf
Germany

+49 211 3870012

© 2020 Orthogen AG

ORTHOGEN_AG_RGB-1024x611.png